Technologies used for cell and gene therapy development have come a long way but there are still important challenges associated with lentivirus manufacture. GMP plasmids account for a substantial ...

Lentiviral vectors are also highly sensitive to temperature and pH changes—as well as to damage caused by shear forces in culture. And this can be a major problem during process development ...

The popularity of viral vector-based gene therapies and vaccines is rapidly growing. However, it is often difficult for scientists to ramp up the generation of these vectors to meet their needs at ...

Thursday, November 14th, 202411:00 AM - 12:30 PM ET Scientists use plasmids as the leading gene delivery technology for a variety of research and clinical applications related to gene therapy.

AstraZeneca currently has seven cell therapy programs in the clinic, led by a BCMA and CD19 dual-targeting CAR-T for multiple myeloma acquired as part of 2023’s Gracell acquisition. However ...

SHANGHAI, May 15, 2025 /PRNewswire/ -- Immunofoco, a company dedicated to advancing cell therapies for solid tumors, announced that its independently developed, innovative lentiviral vector-based ...

In this study, lentiviral vector–transduced autologous CD34+ HSCT was successful in treating severe LAD-I. (Funded by Rocket Pharmaceuticals and the California Institute for Regenerative ...

If we can work out the roles plasmids play inside bacteria, then we can use the information to develop a new generation of therapeutics that can target drug resistant infections.

Contacts Liz Quinn, PhD VP, Marketing 2560 Orchard Pkwy San Jose, CA 95131 [email protected] 650.919.7400 ...

At a median follow-up of 6 years after lentiviral gene therapy, most patients with early cerebral adrenoleukodystrophy and MRI abnormalities had no major functional disabilities. However ...